Documentos clave

Ver Toda la documentación

R6520

Rolipram

Name: Rolipram
Brand: SIGMA

≥98% (HPLC), solid, cAMP-specific phosphodiesterase (PDE4) inhibitor

Sinónimos:

4-[3-(Cyclopentyloxy)-4-methoxyphenyl]-2-pyrrolidinone, ZK 62711

Iniciar sesión para ver los precios por organización y contrato.

Seleccione un Tamaño

Cambiar Vistas

Acerca de este artículo

Fórmula empírica (notación de Hill):

C₁₆H₂₁NO₃

Número CAS:

61413-54-5

Peso molecular:

275.34

NACRES:

NA.77

PubChem Substance ID:

24278196

UNSPSC Code:

41106305

EC Number:

262-771-1

MDL number:

MFCD00270906

Assay:

≥98% (HPLC)

Form:

solid

Quality level:

100

Servicio técnico

¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.

Permítanos ayudarle

Propiedades

Nombre del producto

Rolipram, solid, ≥98% (HPLC)

biological source

synthetic (organic)

Quality Level

100

assay

≥98% (HPLC)

form

solid

color

white to off-white

solubility

H₂O: 0.2 mg/mL, ethanol: 7 mg/mL, DMSO: 7.3 mg/mL

SMILES string

COc1ccc(cc1OC2CCCC2)C3CNC(=O)C3

InChI

1S/C16H21NO3/c1-19-14-7-6-11(12-9-16(18)17-10-12)8-15(14)20-13-4-2-3-5-13/h6-8,12-13H,2-5,9-10H2,1H3,(H,17,18)

InChI key

HJORMJIFDVBMOB-UHFFFAOYSA-N

Gene Information

human ... LITAF(9516), PDE3A(5139), PDE4A(5141), PDE4B(5142), PDE4C(5143), PDE4D(5144), PDE5A(8654), PDE7A(5150)
mouse ... Pde4a(18577)
rat ... Adora1(29290), Pde1b(29691), Pde2a(81743), Pde3a(50678), Pde4a(25638), Pde4b(24626), Pde4c(290646), Pde5a(171115)

Descripción

General description

Rolipram enhances tissue protection, anatomical repair and functional recovery. It is used to treat asthma, arthritis, Huntington′s disease and multiple sclerosis. Rolipram inhibits injury-induced reductions in cyclic AMP, which is associated with acute central nervous system injury. It functions as an antidepressant, stimulates neurite outgrowth and axonal regeneration in the presence of myelin inhibitors.

Application

Rolipram has been used:

to investigate its effects on testicular torsion–detorsion injury(36)
to block the effects of phosphodiesterase-4 (PDE4)(37)
as a component in chemically induced long-term potentiation (cLTP) induction media(38)

Biochem/physiol Actions

Selective cAMP-specific phosphodiesterase (PDE4) inhibitor.

Features and Benefits

This compound is a featured product for Cyclic Nucleotide research. Click here to discover more featured Cyclic Nucleotide products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

This compound is featured on the Phosphodiesterases page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Still not finding the right product?

Explore all of our products under

Clase de almacenamiento

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

Busque por un COA

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Contenido relacionado

Celltransmissions Newsletter

Improved long-term memory via enhancing cGMP-PKG signaling requires cAMP-PKA signaling.

Eva Bollen et al.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 39(11), 2497-2505 (2014-05-13)

Memory consolidation is defined by the stabilization of a memory trace after acquisition, and consists of numerous molecular cascades that mediate synaptic plasticity. Commonly, a distinction is made between an early and a late consolidation phase, in which early refers

Effects of intravenous phosphodiesterase inhibitors and corticosteroids on severe meconium aspiration syndrome.

Ju-Ing Shao et al.

Journal of the Chinese Medical Association : JCMA, 82(7), 568-575 (2019-07-06)

Meconium aspiration syndrome (MAS) is a major cause of severe respiratory failure in near- and full-term neonates. Alleviating inflammation is key to successfully treating severe MAS. Phosphodiesterase (PDE) inhibitors are known to play a role in airway smooth muscle relaxation

CNS Regeneration: Basic Science and Clinical Advances (2011)

Ver todos los artículos relacionados